ArticleClinical epigenetics2025
RASGEF1C methylation for the distinguishment and classification of benign and malignant thyroid tumors.
Article in Clinical epigenetics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundThe incidence of thyroid cancer (TC) has significantly increased, highlighting the need for effective and objective approaches for the early diagnosis of TC. This study aimed to explore RASGEF1C methylation as a biomarker for papillary thyroid cancer (PTC).
methodsFormalin-fixed paraffin-embedded samples from a total of 363 PTC and 409 benign thyroid nodules from multiple centers were analyzed. RASGEF1C methylation profiles were examined via MALDI-TOFF mass spectrometry. Statistical analysis was performed via logistic regression adjusted for covariates, nonparametric tests, and receiver operating characteristic (ROC) analysis. Additionally, 40 follicular thyroid cancer samples, 45 medullary thyroid cancer samples, and 7 anaplastic thyroid samples from three hospitals were afterward collected to compare methylation patterns across subtypes.
resultsHypomethylation of RASGEF1C in PTC was observed vs. BTN (all odds ratios (ORs) ≥ 1.57, p values < 0.001). Stratification analysis revealed a more pronounced association in younger patients, especially for BRAF V600E-positive PTC patients, than in individuals with benign tumors (all ORs ≥ 1.89, p values < 0.001). ROC analysis further demonstrated the outstanding diagnostic power of RASGEF1C hypomethylation for BRAF V600E-positive PTC cases (area under the curve (AUC) = 0.93), for cases < 55 years old (AUC = 0.88), and even for patients with a tumor length ≤ 1 cm (AUC = 0.83). Moreover, we observed the lowest RASGEF1C methylation level in anaplastic thyroid carcinoma, the most aggressive subtype of TC. Our results revealed similar RASGEF1C hypomethylation between chronic lymphocytic thyroiditis and papillary thyroid cancer, whereas RASGEF1C methylation in subacute thyroiditis patients was similar to that in the other benign subtypes.
conclusionOur study revealed RASGEF1C methylation as a promising biomarker for distinguishing and classifying benign and malignant thyroid tumors and even provided epigenetic evidence for the inflammatory-cancer transformation. Nevertheless, the limitation of tissue-based biomarkers should be well noted, and the development of more accessible biomarkers warrants further exploration in the future.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.